Your browser doesn't support javascript.
loading
Melanoma and microbiota: Current understanding and future directions.
Routy, Bertrand; Jackson, Tanisha; Mählmann, Laura; Baumgartner, Christina K; Blaser, Martin; Byrd, Allyson; Corvaia, Nathalie; Couts, Kasey; Davar, Diwakar; Derosa, Lisa; Hang, Howard C; Hospers, Geke; Isaksen, Morten; Kroemer, Guido; Malard, Florent; McCoy, Kathy D; Meisel, Marlies; Pal, Sumanta; Ronai, Ze'ev; Segal, Eran; Sepich-Poore, Gregory D; Shaikh, Fyza; Sweis, Randy F; Trinchieri, Giorgio; van den Brink, Marcel; Weersma, Rinse K; Whiteson, Katrine; Zhao, Liping; McQuade, Jennifer; Zarour, Hassane; Zitvogel, Laurence.
Afiliación
  • Routy B; University of Montreal Research Center (CRCHUM), Montreal, QC H2X 0A9, Canada; Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.
  • Jackson T; Melanoma Research Alliance, 730 15th Street NW, Washington, DC 20005, USA.
  • Mählmann L; Seerave Foundation, The Seerave Foundation, 35-37 New Street, St Helier, JE2 3RA Jersey, UK.
  • Baumgartner CK; Oncology Discovery Research, AbbVie Inc, North Chicago, IL 60064, USA.
  • Blaser M; Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ 08854, USA.
  • Byrd A; Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080, USA.
  • Corvaia N; MaaT Pharma, 69007 Lyon, France.
  • Couts K; Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
  • Davar D; Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Derosa L; Gustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée par la Ligue Contre le Cancer, 94800 Villejuif, France.
  • Hang HC; Departments of Immunology & Microbiology and Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
  • Hospers G; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
  • Isaksen M; Bio-Me, 0349 Oslo, Norway.
  • Kroemer G; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, 75006 Paris, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94905 Villejuif, France; Institut du
  • Malard F; Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
  • McCoy KD; Department of Physiology & Pharmacology, Snyder Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Meisel M; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA USA.
  • Pal S; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Ronai Z; Sanford Burnham Prebys Discovery Medical Research Institute, La Jolla, CA 92037, USA.
  • Segal E; Weizmann Institute of Science, Computer Science and Applied Mathematics Department, 234th Herzel st., Rehovot 7610001, Israel.
  • Sepich-Poore GD; Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Micronoma Inc., San Diego, CA 92121, USA.
  • Shaikh F; Johns Hopkins School of Medicine, Department of Oncology, Baltimore, MD 21287, USA.
  • Sweis RF; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
  • Trinchieri G; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • van den Brink M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Immunology, Sloan Kettering Institute, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
  • Weersma RK; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Whiteson K; Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA.
  • Zhao L; Department of Biochemistry and Microbiology, New Jersey Institute of Food, Nutrition and Health, Rutgers University, New Brunswick, NY 08901, USA.
  • McQuade J; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jmcquade@mdanderson.org.
  • Zarour H; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA. Electronic address: zarourhm@upmc.edu.
  • Zitvogel L; Gustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée par la Ligue Contre le Cancer, 94800 Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT
Cancer Cell ; 42(1): 16-34, 2024 01 08.
Article en En | MEDLINE | ID: mdl-38157864
ABSTRACT
Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of "omics" technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microbiota / Microbioma Gastrointestinal / Melanoma / Neoplasias Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microbiota / Microbioma Gastrointestinal / Melanoma / Neoplasias Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Canadá